


U.S. Pharmacopeia method

Pramipexole Dihydrochloride :Enantiomeric purity



Column	: CHIRALPAK® AD 0.46cmΦ × 25cmL (L51)
Mobile phase	: <i>n</i> -Hexane / dehydrated alcohol / Diethylamine = 850 / 150 / 1 (v / v / v)
Flow rate	: 1.5mL/min.
Injection volume	: 75μL
UV detection	: 254nm

System suitability

Sample:


(System suitability stock solution)

1 mg/mL each of USP Pramipexole Dihydrochloride RS and USP Pramipexole Related Compound D RS in dehydrated alcohol.

(System suitability solution)

0.01 mg/mL each of USP Pramipexole Dihydrochloride RS and USP Pramipexole Related Compound D RS from *System suitability stock solution* in *Mobile phase*.

Relative retention time: Pramipexole Related Compound D (*R*-enantiomer) and Pramipexole (*S*-enantiomer) are 0.5 and 1.0, respectively.



	Requirement	Result
Resolution	≥ 5.0	14.9
Tailing factor for Pramipexole	≤ 2.4	1.22